PET/CT Imaging with Fluorine F 18 4-L-Fluoroglutamine (2S,4R) in Finding Cancer

Inclusion Criteria

• Patients with history of histologically-confirmed solid malignancy and/or lymphoma (histology confirmed by Memorial Sloan-Kettering Cancer Center [MSKCC] Department of Pathology)
• Disease measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or other tumor response criteria from an MSKCC Institutional Review Board (IRB)-approved clinical research protocol; NOTE: Study patients do not need to be participating in an MSKCC approved clinical trial prior to study recruitment
• Negative serum pregnancy test for female patients of childbearing age and potential (as defined by MSKCC standards & guidelines), from assays obtained < 2 weeks prior to study enrollment; patients will be advised against having unprotected sexual intercourse from the time of the negative serum pregnancy test until after completing their participation in the study

Exclusion Criteria

• Inability or refusal to have at least one peripheral intravenous line for intravenous access (as applicable to the day of [18 F] 4-L-Fluoroglutamine (2S,4R) injection and blood draws)
• Breast-feeding
• Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
• Bilirubin > 1.5 x upper limit of normal (ULN) (obtained < 2 weeks prior to study enrollment)
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN (obtained < 2 weeks prior to study enrollment)
• Albumin < 3 g/dl (obtained < 2 weeks prior to study enrollment)
• Gamma-glutamyl transferase (GGT) > 2.5 x ULN IF alkaline phosphatase > 2.5 x ULN (obtained < 2 weeks prior to study enrollment)
• Creatinine > 1.5 x ULN or creatinine clearance < 60 mL/min, from assays obtained < 2 weeks prior to study enrollment
• Acute major illness (e.g., unstable cardiovascular condition, etc.)